The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …

Significant progress has been made within the last 15years in the treatment of advanced
colorectal cancer. Bevacizumab, an anti-vascular endothelial growth factor monoclonal …

The progressively ageing population combined with an increased availability of antitumoural
agents has created a new, challenging therapeutic scenario for oncologists. Due to the lack …

Metastatic colorectal cancer (mCRC), like many cancers, is primarily a disease of elderly
people. Despite this prevalence, such patients are often excluded from randomized trials or …

Background Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy
for patients with metastatic colorectal cancer (mCRC). The relative benefit of bevacizumab in …

Objective Bevacizumab, the first FDA-approved anti-angiogenesis agent, has been used for
metastatic colorectal cancer since 2004. This study evaluated the utilization of bevacizumab …

It is a common belief that older patients and those with less-than-ideal performance status
do not tolerate chemotherapy as well as other patients. In fact, many otherwise-healthy older …

Background: Elderly patients are underrepresented in clinical trials and frequently
undertreated with standard therapy. The BRiTE observational cohort study assessed the …

Background: Although the efficacy and safety of combining first-line chemotherapy with
bevacizumab in elderly patients with colorectal cancer (CRC) is supported by the results of a …

Although major progress has been achieved in the treatment of advanced colorectal cancer
(CRC) with the employment of antiangiogenic agents, several questions remain on the use …